Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Shionogi & Co ( (JP:4507) ) is now available.
Shionogi & Co. has announced that its new drug application for ensitrelvir fumaric acid, a treatment for COVID-19, has been accepted by the Taiwan Food and Drug Administration. Additionally, a contract has been concluded for the Taiwanese government’s stockpiling of the drug, which is expected to contribute significantly as a treatment option for the estimated 1.7 million annual COVID-19 patients in Taiwan. Ensitrelvir, an oral antiviral developed through a collaboration with Hokkaido University, has received regulatory approvals in Japan and Singapore, highlighting its potential impact on the company’s operations and positioning in the pharmaceutical market.
More about Shionogi & Co
Shionogi & Co., Ltd., based in Osaka, Japan, has been a leader in infectious disease discovery and commercialization since 1953. The company focuses on developing medications for various infectious diseases, including HIV, influenza, and COVID-19. Shionogi is also involved in global health initiatives to improve access to antibiotics through partnerships with organizations like the Clinton Health Access Initiative and the Global Antibiotic Research and Development Partnership.
YTD Price Performance: 16.73%
Average Trading Volume: 534
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $12.64B
See more insights into 4507 stock on TipRanks’ Stock Analysis page.
